Perspective Therapeutics 11/14/2023 Earnings Report

Perspective Therapeutics EPS Results

• Actual EPS: -$0.40
• Consensus EPS: -$0.40
• Beat/Miss: Met Expectations
• One Year Ago EPS: N/A

Perspective Therapeutics Revenue Results

• Actual Revenue: $2.19 million
• Expected Revenue: $2.20 million
• Beat/Miss: Missed by -$10.00 thousand
• YoY Revenue Growth: N/A

Perspective Therapeutics Announcement Details

• Date: 11/14/2023
• Time: N/A
• Conference Call Date: N/A
• Conference Call Time: N/A

Perspective Therapeutics (NYSE:CATX) (NYSE:CATX) is a clinical‐stage biotechnology company dedicated to developing ultra‐small targeted radiopharmaceuticals for the treatment and diagnosis of cancer. Leveraging a proprietary platform that conjugates short‐range radioactive isotopes with peptides and antibodies, the company aims to deliver precision radiation directly to tumor sites while minimizing exposure to healthy tissue. Its products are designed to address a range of solid tumors and hematological malignancies, offering both therapeutic and imaging applications.

The company’s pipeline includes several lead candidates in various stages of preclinical and early clinical development. Among these are alpha‐emitting therapeutics targeting prostate cancer, neuroendocrine tumors and other advanced solid tumors. In parallel, Perspective Therapeutics is advancing companion diagnostic agents to improve patient selection and monitor treatment response in real time. Research collaborations with academic medical centers and strategic partnerships with international specialists support ongoing efforts to optimize dosage, enhance tumor targeting and streamline regulatory pathways.

Headquartered in San Mateo, California, Perspective Therapeutics operates research facilities in the United States and maintains collaborative research sites in Europe and Asia. The company’s global footprint allows it to conduct multi‐center clinical trials and engage with regulators across key markets. This international approach is designed to accelerate patient access to novel radiopharmaceuticals and establish a robust data package to support future product approvals.

Founded in 2019, Perspective Therapeutics brings together a leadership team with extensive experience in radiochemistry, oncology drug development and regulatory affairs. Chief Executive Officer Dr. Cynthia Knill has over two decades of experience in nuclear medicine, while Chief Financial Officer Maria Lopez has led multiple biotech financings and public offerings. The board of directors includes industry veterans and academic researchers who guide the company’s strategic direction and foster innovation in targeted cancer therapies.